Type-II Variation: Waive in-vivo study by providing in-vitro data? [Study As­sess­ment]

posted by qualityassurance – 2024-07-02 13:29 (725 d 14:59 ago) – Posting: # 24054
Views: 4,647

Dear Helmut,

Thank you for the response.

Is it possible to waive in-vivo study if we achieve similar in-vitro dissolution profile in multimedia between test products (BE batch vs new formulation) having different particle size?

Regards,
QA

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
370 visitors (0 registered, 370 guests [including 30 identified bots]).
Forum time: 04:29 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5